Ken Keller

Ken Keller is the Chairman of the Board, President and CEO of Daiichi Sankyo, Inc., and Head of the Global Oncology Business responsible for leading the overarching company strategy of ensuring innovative medicines are available to patients with cancer around the world. With more than 30 years of experience in the pharmaceutical industry, Ken has led multi-billion-dollar businesses in both US and Europe while working to unify cross-functional teams to create a global infrastructure – enabling the commercial success of Daiichi Sankyo oncology and specialty medicines. Through leadership roles in multiple markets, across cultures and within different healthcare systems, Ken has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth. With more than 20 years of oncology experience, Ken had a longstanding career at Amgen where he held several leadership roles, with increasing global and commercial responsibility, including Vice President and General Manager, Bone Health Business Unit. Prior to joining Daiichi Sankyo, Ken served as COO at Spectrum Pharmaceuticals, where he held global responsibility for leading commercial operations, medical and clinical development, regulatory, quality, safety and pharmaceutical operations.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.